Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer
A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).